🕒 Friday 28 August 2026 Fri, 28 Aug 2026

Australian Gold and Copper Ltd (ASX: AGC) has reported extensive polymetallic mineralisation at its Evergreen Prospect, delivering high-grade gold, silver, lead, and zinc intercepts. With 17 diamond holes completed and a reverse circulation rig now targeting shallow oxide zones, the company is progressing towards an initial Mineral Resource Estimate.

Broken Hill Mines Limited posted a $48.8 million loss for FY2026, driven by acquisition-related costs and re-compliance expenses, despite a 56% revenue increase reflecting production growth at Rasp and Pinnacles mines.

CleanSpace Holdings is set to repurchase up to 10% of its shares over the next year, signalling confidence in its growth prospects and capital position.

Ashley Services Group delivered a standout FY26 with revenue up 16.7% to $602.2 million and net profit after tax surging 189.5% to $6.29 million, supported by margin gains across key sectors and a strategic acquisition.

Gateway Mining's recent aircore drilling has unveiled a substantial 7-kilometre gold mineralised corridor at the Ward Prospect, expanding the known mineralisation footprint within its Yandal Gold Project and positioning Ward as a significant new target adjacent to the Cowza gold system.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.

Immuron Limited posted a 6% rise in FY26 sales to $7.7 million, improved its net loss by $1.4 million, and secured FDA approval for IMM-529, underpinning a strategic pivot towards profitability and geographic expansion.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

Westgold Resources delivered a landmark FY26 with record gold output, soaring profits, and a strong balance sheet underpinning a 10 cents per share fully franked dividend.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Evolution Mining has taken a significant step toward its full acquisition of Carnaby Resources by acquiring a 13.7% stake from the QIC Queensland Critical Minerals Fund through a share issue, reinforcing its position as Carnaby’s largest shareholder.

Jupiter Mines reported a modest dip in FY2026 net profit to $37.6 million, with its joint venture Tshipi delivering solid production and sales despite rising costs and currency headwinds. The company declared a final dividend of 0.75 cents per share, maintaining its shareholder returns streak.

Austral Gold nearly doubled its gold equivalent production in the first half of 2026, driven by the Casposo restart and Guanaco operations, delivering a US$15.5 million net profit and extending Guanaco’s mine life to 14 years.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Mach7 Technologies reported a 17.4% revenue drop to $27.9 million and a 44% increase in net loss to $8.9 million for FY26, driven by a strategic transition to a subscription model and cost base restructuring.

Frontier Digital Ventures narrowed its focus to core classifieds, resulting in a 27% revenue decline but an 18% rise in EBITDA and a $2.5 million profit in the first half of 2026.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Sea Forest Limited (ASX:SEA) reported a spectacular 486% surge in SeaFeed revenue for FY26, underpinned by 131,000 cattle committed, surpassing breakeven targets, and a robust $27.8 million cash buffer. The company advances its commercial footprint domestically and internationally, with carbon credit revenue set to kick off in late 2027.

Patrys has cleared a key regulatory hurdle with Human Research Ethics Committee approval for its Phase 1A clinical trial of RLS-2202, aiming to start dosing healthy volunteers this quarter.

West Cobar Metals is broadening its scandium exploration at Salazar by adding the Benriach Prospect to its Q4 2026 air-core drilling program, aiming to tap near-surface scandium enrichment and higher-grade zones within its existing resource.

Percheron Therapeutics has partnered with Vanderbilt Health to initiate a clinical trial testing HMBD-002 in combination with standard treatments for high-risk acute myeloid leukaemia and myelodysplastic syndrome, targeting a recruitment start in late 2026.

Virgin Australia Holdings (ASX:VGN) posted a 13.4% rise in underlying EBIT to $753 million for FY26, declaring a fully franked dividend of 7.6 cents per share, its first since relisting. The airline’s transformation program, fleet renewal, and operational resilience underpin its improved financial and customer metrics.